Simple ointment may prevent skin graft infections in rural hospitals
NCT ID NCT07286851
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at whether applying neomycin antibiotic ointment during skin graft surgery reduces infections and improves healing. Researchers reviewed medical records of 142 patients in a rural Bangladesh hospital, comparing those who received the ointment to those who did not. The goal is to find a simple, affordable way to improve skin graft outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- neomycin antibiotic ointment
- What this could lead to
- If it works, this could point toward a simple, low-cost way to reduce infections and improve skin graft success in resource-limited settings.
- What could go wrong
- This is a small, retrospective study (not a randomized trial), so results may be influenced by other factors. The findings may not apply to other hospitals or populations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTIBIOTIC PROPHYLAXIS SURGERY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
LAMB Hospital
Parbatipur, Dinajpur, 5250, Bangladesh
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can whole blood beat component transfusions in trauma?
- Testosterone may rebuild strength after spinal cord injury — trial puts it to the test
- Which humidifier prevents airway blockages in trauma ICU patients?
- Penis transplants could restore form and function for wounded warriors
- Vacuum dressing could cut infections after skin graft surgery
- New hand transplant protocol aims to cut lifelong drug risks